(Q40471195)

20 September 2017

1 reference

title

Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination. (English)

1 reference

20 September 2017

piperacillin/tazobactam

1 reference

L L Schoonover

1

1 reference

20 September 2017

D J Occhipinti

series ordinal

2

1 reference

20 September 2017

K A Rodvold

series ordinal

3

1 reference

20 September 2017

L H Danziger

series ordinal

4

1 reference

20 September 2017

language of work or name

English

0 references

publication date

1 May 1995

1 reference

Annals of Pharmacotherapy

20 September 2017

1 reference

20 September 2017

29

1 reference

20 September 2017

5

1 reference

20 September 2017

501-514

1 reference

The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam

20 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A Metaanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

Effects of sodium piperacillin on platelet function in normal volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F106002809502900510

10.1177/106002809502900510

21 January 2018

Identifiers

DOI

1 reference

20 September 2017

1 reference